Is regorafenib/bevango a targeted therapy drug?

Regorafenib is a multi-target oral small molecule drug mainly used to treat colorectal cancer, gastrointestinal stromal tumors (GIST), liver cancer and other advanced malignant tumors. Its mechanism of action mainly achieves anti-tumor effects by inhibiting multiple cytokine receptors, tyrosine kinases and tumor angiogenesis pathways. Therefore, regorafenib is classified as a targeted therapy.

As a targeted drug, regorafenib inhibits tumor growth and metastasis through specific molecular targets. Unlike traditional chemotherapy drugs, regorafenib can reduce damage to normal cells by selectively acting on specific pathways of tumor cells, thereby reducing side effects. The targets of regorafenib mainly include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), etc. These targets play an important role in the occurrence and development of tumors.

Regorafenib is mainly used in patients with advanced cancer that cannot be surgically removed or has progressed after other treatments. Its multi-target mechanism of action enables it to exert efficacy in multiple tumor types, especially in patients with colorectal cancer and gastrointestinal stromal tumors. By targeting tumor angiogenesis and tumor cell proliferation, regorafenib helps delay disease progression and improve patients' survival and quality of life.

In general, regorafenib is undoubtedly a targeted therapy drug and a multi-target drug. It has a wide range of applications and can provide effective treatment options for patients with a variety of cancers. Especially for those patients who have failed traditional treatments, regorafenib provides an important treatment option.

Keyword tags: Regorafenib,Regorafenib, targeted therapy, cancer treatment, angiogenesis, tyrosine kinase, colorectal cancer, gastrointestinal stromal tumor, liver cancer

Reference materials:https://www.mayoclinic.org/drugs-supplements/regorafenib-oral-route/description/drg-20075822